Chapter 20 of 25
- Confirm pathology, extent and prior treatment
- Integrate molecular group and recurrence risk
- Discuss intent, benefits, harms and patient priorities
- Agree a multidisciplinary plan and reassessment
What you will learn
- Distinguish resectable regional disease from widespread metastases.
- Understand systemic therapy, local treatment and supportive care.
- Ask how molecular findings and previous treatment affect the plan.
Stage III is not the same as distant metastatic disease
Stage III can involve nearby tissues or regional lymph nodes. Stage IV includes specific adjacent-organ involvement, peritoneal spread beyond the pelvis or distant metastases under FIGO 2023. The distribution and volume of disease matter, as do histology, molecular group and fitness. A stage label alone does not determine whether a useful operation is possible.
A multidisciplinary team assesses whether surgery can remove visible disease with acceptable morbidity. Extensive surgery is not beneficial simply because it is technically possible. If complete resection is unlikely or unsafe, systemic therapy may be used first, with reassessment for local treatment in selected responders. This should be a planned strategy with clear goals.
Systemic treatment
Carboplatin/paclitaxel with an appropriate checkpoint inhibitor is a major option for eligible primary advanced or recurrent disease. MMRd cancers tend to show particularly strong immunotherapy benefit, but some combinations are approved regardless of MMR status. A clinician must match the regimen to the exact setting, prior treatment and regional label.
Chemotherapy alone remains relevant when immunotherapy is unsuitable or unavailable. Selected hormone-receptor-positive, low-grade, slowly progressive cancers may be treated hormonally. HER2-directed treatment may apply to selected biomarker-positive disease. These options are not interchangeable, and a favourable biomarker does not remove the need to control serious symptoms promptly.
Local treatment still matters
| Situation | Possible role of local treatment |
|---|---|
| Resected stage III disease | Radiation and systemic therapy to address different recurrence risks |
| Limited metastatic sites | Selected surgery or focused radiation after specialist review |
| Bleeding or painful pelvic mass | Radiation, procedures or surgery for symptom relief |
| Medically inoperable localized disease | Definitive radiation may remain curative |
GOG-258 compared chemoradiotherapy with chemotherapy in mainly stage III–IVA disease. Long-term follow-up did not show an overall-survival improvement from the combined regimen, although local recurrence was reduced. PORTEC-3 used radiation alone as its comparator. The different questions explain why the studies should not be described as contradictory.
Assessing benefit and burden
Scans, symptoms, examination and laboratory tests help assess treatment. Tumour shrinkage is one measure, but stable disease with symptom improvement may also be worthwhile. Worsening symptoms require review even if the next scan is not yet due. Ask when the team will reconsider treatment if benefit is limited or toxicity is high.
Supportive and palliative care can address pain, bleeding, bowel or urinary obstruction, fatigue, emotional distress and family needs while anticancer treatment continues. Early involvement can improve communication and symptom management. It is appropriate to discuss what matters most, including time at home, work, function and avoiding hospital admissions.
Questions and take-home messages
Ask whether the intent is cure, prolonged control or symptom relief; whether surgery is expected to remove all visible disease; and what the next option would be if treatment stops working. Discuss access constraints honestly. A locally available evidence-based option with good supportive care may be more practical than an unaffordable regimen that cannot be monitored safely.
Related chapters
- Recurrent Endometrial Cancer
- Molecular Classification: The Four Major Groups
- How Doctors Choose Treatment
References and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- NRG/GOG-258: long-term overall survival, 2025
- RUBY: overall survival analysis, Annals of Oncology 2024
- FDA pembrolizumab–chemotherapy approval / KEYNOTE-868, June 2024
- FDA expanded dostarlimab–chemotherapy indication, August 2024
- ASCO Palliative Care guideline update, 2024
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy